Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tejilidine vs butorphanol vs sufentanil for postoperative PCA after laparoscopic total hysterectomy
ChiCTR2600118132Phase 4Not yet recruiting
- Sponsor
- Jinan Maternal and Child Care Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tegileridine in Fibromyoma (LM), Cervical Cancer (CC) and postoperative pain (3 arms), sponsored by Jinan Maternal and Child Care Hospital. Primary endpoint: Resting NRS pain score at 2 hours postoperatively. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
Fibromyoma (LM)Cervical Cancer (CC)postoperative pain
Beyond the preview
Go deeper on ChiCTR2600118132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118132.